Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies.,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2018-05-20 , DOI: 10.1200/jco.2018.36.15_suppl.3095
Monica M. Mita ₁ , Alain C. Mita ₂ , Bartosz Chmielowski ₃ , Erika Paige Hamilton ₄ , Shubham Pant ₅ , Roger J. Waltzman ₆ , Eric Keith Rowinsky ₇ , Michael Szarek ₆ , Foster Gonsalves ₆ , Isabel Kurth ₆ , Celia Andreu ₆ , Robert Busby ₈ , David Martin Darst ₆ , Sohail S. Tavazoie ₉ , Masoud Tavazoie ₆ , Michael A. Postow ₁₀

Affiliation

3095Background: RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene. RGX-104 depletes myeloid derived suppressor cells (MDSCs) and...

中文翻译：